Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2024-04-02
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of pevonedistat when given together
with ibrutinib in participants with chronic lymphocytic leukemia or non-Hodgkin lymphoma that
has come back or has stopped responding to other treatments. Pevonedistat and ibrutinib may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Phase:
Phase 1
Details
Lead Sponsor:
City of Hope Medical Center OHSU Knight Cancer Institute